Advertisement
Loading...

Lineage Cell Therapeutics, Inc.

LCTX•AMEX
Healthcare
Biotechnology
$1.30
$-0.02(-1.52%)
U.S. Market opens in 1h 33m
Advertisement

Lineage Cell Therapeutics, Inc. (LCTX) Stock Overview

Explore Lineage Cell Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap324.1M
P/E Ratio-4.96
EPS (TTM)$-0.29
ROE-1.52%
Fundamental Analysis

AI Price Forecasts

1 Month$1.74
3 Months$1.94
1 Year Target$2.42

LCTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Lineage Cell Therapeutics, Inc. (LCTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 40.56, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.42.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.96 and a market capitalization of 324.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.52%
5-Day Change
8.33%
1-Month Change
-16.13%
3-Month Change
-31.58%
6-Month Change
-25.29%
Year-to-Date (YTD) Change
-22.16%
1-Year Change
90.36%
3-Year Change
1.56%
5-Year Change
-43.72%
All-Time (Max) Change
-66.81%

Contact Information

https://www.lineagecell.com
442 287 8990
2173 Salk Avenue, Carlsbad, CA, 92008

Company Facts

70 Employees
IPO DateMar 5, 1992
CountryUS
Actively Trading

Frequently Asked Questions